Afficher la notice abrégée

Faut-il limiter la durée des traitements par benzodiazepines ?

dc.rights.licenseopenen_US
dc.contributor.authorVORSPAN, F.
dc.contributor.authorBARRE, T.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
dc.contributor.authorMONTASTRUC, Francois
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDAUBECH-TOURNIER, Marie
dc.date.accessioned2021-01-06T12:50:21Z
dc.date.available2021-01-06T12:50:21Z
dc.date.issued2018-10
dc.identifier.issn0755-4982en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/23708
dc.description.abstractEnBenzodiazepines and Z-drugs have pharmacodynamic effects with tolerance that can occur quickly, after one week to one month of treatment and that concerns hypnotic and anxiolytic properties in particular. Old studies showed a real but poor short-term efficacy of benzodiazepines on anxiety and sleep disturbances. Long-term efficacy of benzodiazepines can be confused with the occurrence of rebound effect, discontinuation symptoms or relapse when the treatment is quitted; they contribute to an apparent efficacy, as well as the symptoms removal when treatment is re-initiated. Pharmacologic tolerance exists with respects to efficacy and side effects that decrease over time, in the first weeks of treatment. Its main associated characteristic is the occurrence of a severe withdrawal syndrome when treatment is quitted. To limit long-term treatments, it is relevant to target treatment initiation of benzodiazepines and to restrict indications and treatment duration. Addiction to benzodiazepines is frequent in patients treated for another addiction; it is associated with more frequent complications, in particular overdoses and suicide attempts. The use of benzodiazepines is necessary to prevent complications during alcohol or benzodiazepine withdrawal, but duration of treatment should be limited and dispensing should be supervised in patients with substance use disorders.
dc.language.isoFRen_US
dc.subject.enPharmacoEpi-Drugs
dc.titleFaut-il limiter la durée des traitements par benzodiazepines ?
dc.title.alternativePresse Meden_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.lpm.2018.10.006en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30454582en_US
bordeaux.journalPresse medicale (Paris, Franceen_US
bordeaux.page892-898en_US
bordeaux.volume47en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue10en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03099970
hal.version1
hal.date.transferred2021-01-06T12:50:25Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.title=Faut-il%20limiter%20la%20dur%C3%A9e%20des%20traitements%20par%20benzodiazepines%20?&rft.atitle=Faut-il%20limiter%20la%20dur%C3%A9e%20des%20traitements%20par%20benzodiazepines%20?&rft.jtitle=Presse%20medicale%20(Paris,%20France&rft.date=2018-10&rft.volume=47&rft.issue=10&rft.spage=892-898&rft.epage=892-898&rft.eissn=0755-4982&rft.issn=0755-4982&rft.au=VORSPAN,%20F.&BARRE,%20T.&PARIENTE,%20Antoine&MONTASTRUC,%20Francois&DAUBECH-TOURNIER,%20Marie&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée